Skip to main content

Enhancement of an advanced clinical trial recruitment platform for Europe to ensure maximum intake of eligible consenting patients for participation

Periodic Reporting for period 1 - CliniTrial (Enhancement of an advanced clinical trial recruitment platform for Europe to ensure maximum intakeof eligible consenting patients for participation)

Reporting period: 2016-11-01 to 2017-04-30

Viomedo’s mission is to improve people’s lives by connecting patients in need with cutting-edge research in order to advance medical practice together. The overall goal is to establish Viomedo as the central European clinical development platform connecting patients with clinical trials, thereby accelerating patient’s access to medical innovation and strengthening attractiveness of research in the EU. Viomedo also supports the EU goal of increasing transparency in clinical trials and patient engagement.
The overall objective of the project is to successfully roll out, commercialise and establish the Viomedo patient-centric clinical trials platform across first three European countries outside of Germany.
In the phase I feasibility study, the prototype of Viomedo for the German market was analysed regarding its potential to serve the European market. The study included market validation, user need identification, analysis of the competition, identification of technical requirements and evaluation of Viomedo’s pricing strategy. The goal was to develop the steps necessary to get Viomedo from development stage TRL6 to TRL8.
To identify the requirements of Viomedo’s clients, interviews with all parties involved in a trial were conducted. Evaluation of answers of 120 patients from several European countries confirmed their demand for comprehensible trial information and access. Discussion with 4 leading patient advocacy groups validated these results.
The pharmaceutical industry’s main goal is to reduce the recruitment time of their clinical trials in order to get to market faster. Interviews with over 100 international researchers, study coordinators and clinical investigators validated their demand for higher patient recruitment numbers and shorter timelines.
The European market for patient recruitment has a size of $3,5 billion. Across Europe there is a need for a central platform that connects patients with clinical research. Current patient recruitment solutions offered in Europe do not provide a comprehensive solution. Viomedo represents the first patient centric trial platform that offers researchers and pharmaceutical companies effective patient recruitment and feasibility services for their clinical trials.
An IPR protection study assured that Viomedo does not infringe upon IP rights of any of the competitors. Additionally, an IP protection strategy was developed in order to build up a competitive moat.
Legal requirements for data security across Europe were analysed and considered on the product and business development roadmap. Furthermore, Viomedo’s pricing strategy was validated and a risk management plan created.
Based on the results of the feasibility study, the prototype of Viomedo is prepared for the European market. Once Viomedo expands across the EU, it will help patients to benefit from innovative research earlier and support development of novel therapies. Viomedo has the potential to turn the EU into a more attractive region for clinical research.
Trough improvement of patient recruitment, Viomedo provides a solution for accelerating trial conduction and reversion of increasing costs and timelines for development of novel therapies. At the same time with the publicly available clinical trial platform, Viomedo creates an important benefit for health education of European citizen. For the first time, patients and their relatives can, independently from social status, education or location access information on clinical trials in an easy comprehensible language and can inform themselves on all available treatment options